Highlights: • More than 99.9% effective against full suite of ESKAPE pathogens, within hours of exposure to RECCE® 327 (R327) in independent bacterial efficacy studies • R327 remains effective against hypermutated ESKAPE superbugs, including MultiDrug Resistant (MDR) forms - a current market challenge of all existing antibiotics • On-track to be the only company developing an efficacious anti-infective against ESKAPE pathogens globally Sydney Australia, 4 May 2021: Recce Pharmaceuticals Ltd (ASX:RCE) (FSE:R9Q) (Company), the Company developing New Classes of Synthetic Anti-infectives, is pleased to announce RECCE® 327 (R327) has demonstrated bactericidal activity against all six antibiotic resistant ESKAPE pathogens, including drug resistant mutations (superbugs) as well as two additional World Health Organisation (WHO) priority pathogens list. These antibiotic resistant bacteria acronymically dubbed 'ESKAPE’ due to their propensity of 'escaping' the biocidal action of antibiotics, are collectively responsible for over 720,000 hospital acquired (nosocomial) infections in the United States alone each year. 1 The ESKAPE pathogens include both Gram-positive and Gram-negative bacteria; Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species. The study was conducted by an independent Contract Research Organisation to assess the in-vitro efficacy of R327 against all ESKAPE pathogen bacterial strains. R327 is a broad-spectrum synthetic anti-infective that has potential to address the urgent global health threat posed by antibiotic resistant superbugs and emerging viral pathogens.
RCE Price at posting:
$1.13 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)